Cervomed INC 8-K filings

CervoMed presented biomarker data from its Phase 2a trial showing neflamapimod significantly reduced a key protein marker in patients with dementia with Lewy bodies, and also presented preclinical data supporting its potential in tau-related diseases.

CervoMed Inc. amended a pre-funded warrant held by the Joshua S. Boger 2021 Trust, removing a restriction on ownership and allowing the trust to fully exercise the warrant.

CervoMed appoints Joshua Boger, founder of Vertex Pharmaceuticals, as Board Chair and announces participation in an investor conference, while remaining on track with its Phase 2b clinical trial for neflamapimod.

CervoMed Inc. has formalized new employment agreements with its CEO, COO, and Senior VP of Clinical Development, outlining their compensation and severance terms.